A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
Dupixent peak sales ambition raised to more than €13 billion
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Subscribe To Our Newsletter & Stay Updated
